Selected research
Industry Research
Aneurysmal Subarachnoid Hemorrhage Drugs Industry Research Report 2026
Market perspective
The global Aneurysmal Subarachnoid Hemorrhage Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Aneurysmal Subarachnoid Hemorrhage Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Aneurysmal Subarachnoid Hemorrhage Drugs include Arbor Pharmaceuticals, Orexo AB, PDS Biotechnology Corporation, Pharmaxis, Purdue Pharma, Pfizer, Mylan N.V, Johnson and Johnson and Sun Pharmaceutical Industries, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Aneurysmal Subarachnoid Hemorrhage Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Aneurysmal Subarachnoid Hemorrhage Drugs Market by Company
Arbor Pharmaceuticals
Orexo AB
PDS Biotechnology Corporation
Pharmaxis
Purdue Pharma
Pfizer
Mylan N.V
Johnson and Johnson
Sun Pharmaceutical Industries
Teva Pharmaceutical
Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Type
Osmotic Agent
Anticonvulsant
Calcium Channel Blocker
Stool Softener
Opioid Analgesic
Other Drugs
Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Application
Hospital
Clinic
Others
Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aneurysmal Subarachnoid Hemorrhage Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Aneurysmal Subarachnoid Hemorrhage Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aneurysmal Subarachnoid Hemorrhage Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Aneurysmal Subarachnoid Hemorrhage Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Aneurysmal Subarachnoid Hemorrhage Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Aneurysmal Subarachnoid Hemorrhage Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Osmotic Agent
- Anticonvulsant
- Calcium Channel Blocker
- Stool Softener
- Opioid Analgesic
- Other Drugs
Applications
- Hospital
- Clinic
- Others
Companies covered
- Arbor Pharmaceuticals
- Orexo AB
- PDS Biotechnology Corporation
- Pharmaxis
- Purdue Pharma
- Pfizer
- Mylan N.V
- Johnson and Johnson
- Sun Pharmaceutical Industries
- Teva Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size (2021-2032)
- 2.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (2021-2032)
- 2.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Average Price (2021-2032)
- 2.3 Aneurysmal Subarachnoid Hemorrhage Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Osmotic Agent
- 2.3.3 Anticonvulsant
- 2.3.4 Calcium Channel Blocker
- 2.3.5 Stool Softener
- 2.3.6 Opioid Analgesic
- 2.3.7 Other Drugs
- 2.4 Aneurysmal Subarachnoid Hemorrhage Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Aneurysmal Subarachnoid Hemorrhage Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Aneurysmal Subarachnoid Hemorrhage Drugs, Product Type & Application
- 3.8 Global Manufacturers of Aneurysmal Subarachnoid Hemorrhage Drugs, Established Date
- 3.9 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Arbor Pharmaceuticals
- 4.1.1 Arbor Pharmaceuticals Company Information
- 4.1.2 Arbor Pharmaceuticals Business Overview
- 4.1.3 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.1.5 Arbor Pharmaceuticals Recent Developments
- 4.2 Orexo AB
- 4.2.1 Orexo AB Company Information
- 4.2.2 Orexo AB Business Overview
- 4.2.3 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.2.5 Orexo AB Recent Developments
- 4.3 PDS Biotechnology Corporation
- 4.3.1 PDS Biotechnology Corporation Company Information
- 4.3.2 PDS Biotechnology Corporation Business Overview
- 4.3.3 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.3.5 PDS Biotechnology Corporation Recent Developments
- 4.4 Pharmaxis
- 4.4.1 Pharmaxis Company Information
- 4.4.2 Pharmaxis Business Overview
- 4.4.3 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.4.5 Pharmaxis Recent Developments
- 4.5 Purdue Pharma
- 4.5.1 Purdue Pharma Company Information
- 4.5.2 Purdue Pharma Business Overview
- 4.5.3 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.5.5 Purdue Pharma Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Mylan N.V
- 4.7.1 Mylan N.V Company Information
- 4.7.2 Mylan N.V Business Overview
- 4.7.3 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.7.5 Mylan N.V Recent Developments
- 4.8 Johnson and Johnson
- 4.8.1 Johnson and Johnson Company Information
- 4.8.2 Johnson and Johnson Business Overview
- 4.8.3 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.8.5 Johnson and Johnson Recent Developments
- 4.9 Sun Pharmaceutical Industries
- 4.9.1 Sun Pharmaceutical Industries Company Information
- 4.9.2 Sun Pharmaceutical Industries Business Overview
- 4.9.3 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.9.5 Sun Pharmaceutical Industries Recent Developments
- 4.10 Teva Pharmaceutical
- 4.10.1 Teva Pharmaceutical Company Information
- 4.10.2 Teva Pharmaceutical Business Overview
- 4.10.3 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
- 4.10.5 Teva Pharmaceutical Recent Developments
5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Scenario by Region
- 5.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021-2032
- 5.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021-2026
- 5.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2027-2032
- 5.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region: 2027-2032
- 5.4 North America Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
- 5.4.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
- 5.4.3 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
- 5.5.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
- 5.7.1 South America Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
- 5.7.3 South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2021-2032)
- 6.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2021-2032)
- 7.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Aneurysmal Subarachnoid Hemorrhage Drugs Value Chain Analysis
- 8.1.1 Aneurysmal Subarachnoid Hemorrhage Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Aneurysmal Subarachnoid Hemorrhage Drugs Production Mode & Process
- 8.2 Aneurysmal Subarachnoid Hemorrhage Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Distributors
- 8.2.3 Aneurysmal Subarachnoid Hemorrhage Drugs Customers
9 Global Aneurysmal Subarachnoid Hemorrhage Drugs Analyzing Market Dynamics
- 9.1 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends
- 9.2 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Drivers
- 9.3 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Opportunities and Challenges
- 9.4 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst